Invitae News

[Invitae News @InvitaeNews]

National data privacy proposal may shape health data not covered by HIPAA https://t.co/Aipydz5QBL

[mendelspod @mendelspod]

What the future of a genetic testing company looks like.

Our interview with @Invitae's General Manager of Data, Farid Vij.

https://t.co/yZWG6XEVMB

[Ed Esplin, MD, PhD @EdEsplin]

"#Universal #Germline #GeneticTesting for Hereditary Cancer Syndromes in #Patients With Solid Tumor #Cancer"

@judygarber5 @DrHQRana @DanaFarber @HHampel1 @cityofhope @J_Samadder @MayoClinic #DrNealShore @CURCMB @Invitae in @JCOPO_ASCO @ASCO

https://t.co/gKD8dVL1ol

[Invitae News @InvitaeNews]

Out today @Invitae study in collaboration with @NUFeinbergMed shows 66% of patients with positive cardiomyopathy or arrhythmia #GeneticTesting have management implications. Appears in @JAMACardio: https://t.co/ZsZ9FIVS2X

[Invitae News @InvitaeNews]

#PrecisionMedicine #GeneticTesting

[Ed Esplin, MD, PhD @EdEsplin]

#Germline #genetictesting & response to #temozolomide in #patients w/ #pheochromocytoma & #paraganglioma

@KimPerez_DFCI et al. @DanaFarber @Invitae in @EndoCancer @Soc_Endo

#access #germlinetesting #precisionmedicine
https://t.co/fnsidwFGr3

[Invitae News @InvitaeNews]

Our recent study found for cascade testing, if the first person who took the #GeneticTest in the family had a proactive test the uptake from other family members was significantly lower than if the first person had a diagnostic test. Read on @frontiersin: https://t.co/TGorGyNRhG

[Invitae News @InvitaeNews]

New Research Demonstrates #Genetic Information Can Transform #CancerCare, Guidelines Remain a Barrier to Patient Access. @Invitae at #ASCO22 https://t.co/TwMDov2TLU

[Invitae News @InvitaeNews]

@Invitae new data show systematic use of phenotype evidence in clinical #GeneticTesting reduces the frequency of variants of uncertain significance and can provide patients with more definitive answers.

Study in American Journal of Medical Genetics: https://t.co/6EKe9iouZF

[Invitae News @InvitaeNews]

Introducing the commercial availability of @Invitae’s expanded #Pharmacogenomics (PGx) Panel which includes the specialized Mental Health Panel and access to a clinical decision support tool. Learn more: https://t.co/Vm8kXLkYHu

Press release: https://t.co/AGQEyyQPXg

[Invitae News @InvitaeNews]

Data show patients with #TesticularCancer and another cancer or a family history of cancer are twice as likely to have at least one #pathogenic #germline variant. Appears in @UrolOncol.
https://t.co/qF7KZLzgHI

[Invitae News @InvitaeNews]

#genomics #genetics

[Allelica @Allelica_PRS]

We are working together with @Invitae to increase equity across diverse ancestries in genomic medicine and to ensure integration of genomic information into breast cancer risk assessments can benefit all women. #genomics #genetics #polygenic https://t.co/xfZsfewX0z @InvitaeNews

[Invitae News @InvitaeNews]

#ACOG2022

[Invitae News @InvitaeNews]

Study highlights the outcomes of germline testing in patients with urothelial carcinoma. #BRCA1/2 #Lynch syndrome were most common findings. Appears in @GIMJournal
Study: https://t.co/oojZ2g1NtK

[Definitive Healthcare @DefinitiveHC]

This week Kamal Gogineni & Dr. Rakesh Patel from @Invitae join @JustinSteinman on the Definitively Speaking #podcast to explore the growth of #GeneticTesting, how #providers can leverage #GeneticData & what it means for #PrecisionMedicine.

Listen here: https://t.co/FTiSAtigbR

[Invitae News @InvitaeNews]

@Invitae’s Dr. Rakesh Patel & Kamal Gogineni joined the latest episode of the Definitively Speaking podcast to discuss how #InvitaeDigitalHealth is leveraging #genomic insights to inform #clinical decisions.

Listen here: https://t.co/Oa0BJOZasF

[Invitae News @InvitaeNews]

Cross-sectional study of prostate cancer patients showed 37% of those with a #pathogenic #germline variant would not meet genetic testing guidelines based on family history.. Appears in @JAMANetwork
Study: https://t.co/pvMFjlSvry

[Invitae News @InvitaeNews]

Study of renal cell carcinoma (RCC) patients found germline FH variants were more frequent among patients with African ancestry versus CHEK2 germline variants in those with non-African ancestry. Appears in @CellReports
Study: https://t.co/jdkkACFIRs

[Invitae News @InvitaeNews]

A recent study with @Invitae and collaborators shows patients with testicular cancer, especially those with a family history of cancer, may benefit from genetic evaluation. Appears in @sciencedirect
Study: https://t.co/eoYKyxXxtq

[Invitae News @InvitaeNews]

@Invitae launches the first comprehensive #genetictesting package for Neurodevelopmental Disorders (NDD). The #NDD package provides actionable #genetic insights for children with developmental disabilities. #affordable #fastresults
Press release: https://t.co/ArD1VAWxFC

[Invitae News @InvitaeNews]

@​Invitae’s Digital Health Platform. Redefining population #healthmanagement by connecting ​#​genomic insights to inform #clinical decisions for patients. #InvitaeDigitalHealth
Press release: https://t.co/IDHhZqZcc3